Can strategies targeting cleaved MUC1 overcome resistance to trastuzumab?

By Araki Kazuhiro  

Breast Cancer Research and Treatment, Vol. 127, Iss. 2, 2011-06 ,pp. : 589-590

Springer Publishing Company

Access to resources Recommend Favorite

“Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future?

By Margariti Nadia  

Breast Cancer Research and Treatment, Vol. 128, Iss. 3, 2011-08 ,pp. : 599-606

Springer Publishing Company

Access to resources Recommend Favorite

Nordihydroguaiaretic Acid (NDGA) Inhibits the IGF-1 and c-erbB2/HER2/neu Receptors and Suppresses Growth in Breast Cancer Cells

By Youngren Jack  

Breast Cancer Research and Treatment, Vol. 94, Iss. 1, 2005-11 ,pp. : 37-46

Springer Publishing Company

Access to resources Recommend Favorite

Epigenetic therapy for cisplatin resistance in non-small-cell lung cancer: the way forward?

By Gao Yun   Baird Anne-Marie   Barr Martin   Gately Kathy   O'Byrne Kenneth J   Gray Steven G  

Lung Cancer Management, Vol. 2, Iss. 1, 2013-02 ,pp. : 1-4

Future Medicine

Access to resources Recommend Favorite

Mechanisms of resistance to trastuzumab: an updated review

By Zhang Yan   Zhang Jinsheng  

The Chinese-German Journal of Clinical Oncology, Vol. 9, Iss. 11, 2010-11 ,pp. : 660-665

Springer Publishing Company

Access to resources Recommend Favorite